8-K - ORIC Pharmaceuticals, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

ORIC Pharmaceuticals presented a rinzimetostat (ORIC-944) program update on March 31, 2026, announcing the selection of a provisional Phase 3 dose and plans to initiate a first Phase 3 trial in post-abiraterone mCRPC in 1H 2026.

Key Takeaways

1Rinzimetostat 400 mg QD with darolutamide selected as the provisional recommended Phase 3 dose (RP3D).

2First Phase 3 trial in post-abiraterone mCRPC is expected to initiate in the first half of 2026.

3Dose optimization data shows a 5-month rPFS of 84% and PSA50 of 33% for the rinzimetostat combination.

4The safety profile is differentiated with no Grade 4/5 events and majority of AEs being Grade 1.

5Post-abiraterone mCRPC represents a $3.5 billion total addressable market annually in the US.

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

| Other Events. | |---|---| ORIC Pharmaceuticals, Inc. (the “Company”) presented a rinzimetostat (ORIC-944) program update (the “Program Update”) on March 31, 2

Other Event

9.01

| Financial Statements and Exhibits. | |---|---| (d) Exhibits. Exhibit Number: 99.1 | Description: Presentation Exhibit Number: 104 | Description: Cover Page In

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1